Drug Approval | February 01, 2024
Orchid Pharma's Exblifeb granted EMA approval
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
The registered capital of the newly founded company is € 50 million
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay’s Avenova products
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
10+ emerging markets, Japan & ANZ transition in final phase
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Subscribe To Our Newsletter & Stay Updated
